Response to crizotinib in a non-small-cell lung cancer patient harbori

Cristina Aguado,1,* Maria-de-los-Llanos Gil,2,* Zaira Yeste,1 Ana Giménez-Capitán,1 Cristina Teixidó,1 Niki Karachaliou,2 Santiago Viteri,2 Rafael Rosell,1,2 Miguel A Molina-Vila1 1Laboratory of Oncology, Pangaea Oncology, 2Dr Rosell Oncology Institute, Quirón Dexeus College Hospital, Barcelona, Spain*These authors contributed equally to this work Summary: Fusion of the anaplastic lymphoma receptor tyrosine kinase gene (ALK) with the echinoderm microtubule-associated protein four gene (EML4) is the second most typical actionable alteration in non-small-cell lung most cancers, with a frequency of 5%. Right here, we current a case of an EML4-ALK-positive affected person with an atypical in-frame insertion from the LTBP1 gene within the canonical junction of variant 1. The affected person was a 39-year-old never-smoker feminine recognized with Stage IV lung adenocarcinoma. A core biopsy was destructive for EGFR and KRAS mutations however constructive for ALK immunohistochemistry and fluorescence in situ hybridization. When submitted to nCounter, the pattern confirmed a three’/5′ imbalance indicative of an ALK rearrangement, however failed to provide a constructive sign for any of the variants examined. Lastly, a band with a molecular weight greater than anticipated appeared after reverse transcriptase-polymerase chain response evaluation. When Sanger sequencing was carried out, the band revealed an atypical EML4-ALK fusion gene with an in-frame 129 bp insertion. A 115 bp phase of the insertion corresponded to an intronic area of LTBP1, a gene positioned within the quick arm of chromosome 2, between ALK and EML4. The affected person acquired crizotinib and confirmed therapeutic response that’s nonetheless ongoing after 12 months. Our consequence means that quick in-frame insertions of different genes within the EML4-ALK junction don’t have an effect on the sensitivity of the EML4-ALK fusion protein to crizotinib. Key phrases: lung most cancers, NSCLC, EML4-ALK, LTBP1, crizotinib, focused remedy

This work is revealed and licensed by Dove Medical Press Restricted. The complete phrases of this license can be found at https://www.dovepress.com/phrases.php and incorporate the Inventive Commons Attribution – Non Business (unported, v3.zero) License.

By accessing the work you hereby settle for the Phrases. Non-commercial makes use of of the work are permitted with none additional permission from Dove Medical Press Restricted, supplied the work is correctly attributed. For permission for business use of this work, please see paragraphs four.2 and 5 of our Phrases.

Obtain Article [PDF]   

LEAVE A REPLY

Please enter your comment!
Please enter your name here